Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Glenn F. Van Wigcheren, Nienke De Haas, Tom A. Mulder, Sophie K. Horrevorts, Martine Bloemendal, Simone Hins-Debree, Yumeng Mao, Rolf Kiessling, Carla M.L. van Herpen, Georgina Flórez-Grau, Stanleyson V. Hato & I. Jolanda M. De Vries. (2021) Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients. OncoImmunology 10:1.
Read now
Read now
Articles from other publishers (45)
Jhon Jairo Calderon, Karol Prieto, Paola Lasso, Susana Fiorentino & Alfonso Barreto. (2023) Modulation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment by Natural Products. Archivum Immunologiae et Therapiae Experimentalis 71:1.
Crossref
Crossref
Ke Tan, Zixuan Fang, Lingzhen Kong, Chen Cheng, Sydney Hwang & Min Xu. (2023) Pan-cancer analyses reveal GTSE1 as a biomarker for the immunosuppressive tumor microenvironment. Medicine 102:34, pages e34996.
Crossref
Crossref
Vanessa Araújo Varela, Letícia Borges da Silva Heinen, Luciana Cavalheiro Marti, Victória Bulcão Caraciolo, Tarcila Santos Datoguia, Mariane Tami Amano & Welbert Oliveira Pereira. (2023) In vitro differentiation of myeloid suppressor cells (MDSC-like) from an immature myelomonocytic precursor THP-1. Journal of Immunological Methods 515, pages 113441.
Crossref
Crossref
Nabeel Kajihara, Takuto Kobayashi, Ryo Otsuka, Junko Nio-Kobayashi, Tomohiro Oshino, Masato Takahashi, Seiichi Imanishi, Ari Hashimoto, Haruka Wada & Ken-ichiro Seino. (2022) Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer. Cancer Immunology, Immunotherapy 72:4, pages 851-864.
Crossref
Crossref
Kathryn Cole, Zaid Al-Kadhimi & James E. Talmadge. (2023) Role of myeloid-derived suppressor cells in tumor recurrence. Cancer and Metastasis Reviews 42:1, pages 113-142.
Crossref
Crossref
Jun Huang, Xuedong Chen, Zaoshang Chang, Chuli Xiao & Masoud Najafi. (2023) Boosting Anti-tumour Immunity Using Adjuvant Apigenin. Anti-Cancer Agents in Medicinal Chemistry 23:3, pages 266-277.
Crossref
Crossref
Ting Li, Mayassa J Bou-Dargham, Norman Fultang, Xinyuan Li, Warren S Pear, Honghong Sun & Youhai H Chen. (2022) c-Rel-dependent monocytes are potent immune suppressor cells in cancer. Journal of Leukocyte Biology 112:4, pages 845-859.
Crossref
Crossref
T. Wen, C. Su, X. Cheng, Y. Wang, T. Ma, Z. Bai, H. Zhang & Z. Liu. (2022) Circulating myeloid-derived suppressors cells correlate with clinicopathological characteristics and outcomes undergoing neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Clinical and Translational Oncology 24:6, pages 1184-1194.
Crossref
Crossref
Jen-Chin Wang & Lishi Sun. (2022) PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review. International Journal of Molecular Sciences 23:10, pages 5837.
Crossref
Crossref
Peter Rose, Natasja K. van den Engel, Julia R. Kovács, Rudolf A. Hatz, Louis Boon & Hauke Winter. (2022) Anti-Gr-1 Antibody Provides Short-Term Depletion of MDSC in Lymphodepleted Mice with Active-Specific Melanoma Therapy. Vaccines 10:4, pages 560.
Crossref
Crossref
Daniel J. García-Domínguez, Lourdes Hontecillas-Prieto, Natalia Palazón-Carrión, Carlos Jiménez-Cortegana, Víctor Sánchez-Margalet & Luis de la Cruz-Merino. (2022) Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics. Cancers 14:6, pages 1469.
Crossref
Crossref
Maria Dulfary Sanchez-Pino, William S. Richardson, Jovanny Zabaleta, Ramesh Thylur Puttalingaiah, Andrew G. Chapple, Jiao Liu, Yonghyan Kim, Michelle Ponder, Randi DeArmitt, Lyndsey Buckner Baiamonte, Dorota Wyczechowska, Liqin Zheng, Amir A. Al-Khami, Jone Garai, Rachel Martini, Melissa Davis, Jessica Koller Gorham, James B. Wooldridge, Paulo C. Rodriguez, Lucio Miele & Augusto C. Ochoa. (2022) Increased inflammatory low-density neutrophils in severe obesity and effect of bariatric surgery: Results from case-control and prospective cohort studies. eBioMedicine 77, pages 103910.
Crossref
Crossref
Filippos Koinis, Anastasia Xagara, Evangelia Chantzara, Vassiliki Leontopoulou, Chrissovalantis Aidarinis & Athanasios Kotsakis. (2021) Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives. Cells 11:1, pages 20.
Crossref
Crossref
Xueqi Yan, Yinghong Xie, Fan Yang, Yijia Hua, Tianyu Zeng, Chunxiao Sun, Mengzhu Yang, Xiang Huang, Hao Wu, Ziyi Fu, Wei Li, Shiping Jiao & Yongmei Yin. (2021) Comprehensive description of the current breast cancer microenvironment advancements via single-cell analysis. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Crossref
Chenfeng Han, Minmin Ge, Ping-Chih Ho & Lianjun Zhang. (2021) Fueling T-cell Antitumor Immunity: Amino Acid Metabolism Revisited. Cancer Immunology Research 9:12, pages 1373-1382.
Crossref
Crossref
Marthe Jøntvedt Jørgensen, Synne Jenum, Kristian Tonby, Rasmus Mortensen, Gerhard Walzl, Nelita Du Plessis & Anne Ma Dyrhol-Riise. (2021) Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors. Journal of Leukocyte Biology 110:1, pages 177-186.
Crossref
Crossref
Carlos Jiménez-Cortegana, Natalia Palazón-Carrión, Alejandro Martin Garcia-Sancho, Esteban Nogales-Fernandez, Fernando Carnicero-González, Eduardo Ríos-Herranz, Fatima de la Cruz-Vicente, Guillermo Rodríguez-García, Rubén Fernández-Álvarez, Antonio Rueda Dominguez, Maria Casanova-Espinosa, Natividad Martínez-Banaclocha, Josep Gumà-Padrò, José Gómez-Codina, Jorge Labrador, Antonio Salar-Silvestre, Delvys Rodriguez-Abreu, Laura Galvez-Carvajal, Mariano Provencio, Margarita Sánchez-Beato, María Guirado-Risueño, Pablo Espejo-García, Marylene Lejeune, Tomás Álvaro, Victor Sánchez-Margalet & Luis de la Cruz-Merino. (2021) Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial. Journal for ImmunoTherapy of Cancer 9:6, pages e002323.
Crossref
Crossref
Kathryn Cole, Kristina Pravoverov & James E. Talmadge. (2021) Role of myeloid-derived suppressor cells in metastasis. Cancer and Metastasis Reviews 40:2, pages 391-411.
Crossref
Crossref
Irina Vladimirovna Gribkova & A.A. Zavyalov. (2021) Multiple Myeloma and Dendritic Cell Vaccines. Clinical oncohematology 14:3, pages 370-377.
Crossref
Crossref
Kai Yin, Xueli Xia, Ke Rui, Tingting Wang & Shengjun Wang. (2020) Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression. Frontiers in Oncology 10.
Crossref
Crossref
Francesco Manfredi, Beatrice Claudia Cianciotti, Alessia Potenza, Elena Tassi, Maddalena Noviello, Andrea Biondi, Fabio Ciceri, Chiara Bonini & Eliana Ruggiero. (2020) TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. Frontiers in Immunology 11.
Crossref
Crossref
Mahmoud Mohammad Yaseen, Nizar Mohammad Abuharfeil, Homa Darmani & Ammar Daoud. (2020) Mechanisms of immune suppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine. Open Biology 10:9.
Crossref
Crossref
Andrew M. K. Law, Fatima Valdes-Mora & David Gallego-Ortega. (2020) Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. Cells 9:3, pages 561.
Crossref
Crossref
Paola De Cicco, Giuseppe Ercolano, Valentina Rubino, Giuseppe Terrazzano, Giuseppina Ruggiero, Giuseppe Cirino & Angela Ianaro. (2019) Modulation of the functions of myeloid‐derived suppressor cells : a new strategy of hydrogen sulfide anti‐cancer effects. British Journal of Pharmacology 177:4, pages 884-897.
Crossref
Crossref
Eleni-Kyriaki Vetsika, Aristeidis Koukos & Athanasios Kotsakis. (2019) Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer. Cells 8:12, pages 1647.
Crossref
Crossref
Julian Mohrherr, Marcel Haber, Kristina Breitenecker, Petra Aigner, Stefan Moritsch, Viktor Voronin, Robert Eferl, Richard Moriggl, Dagmar Stoiber, Balázs Győrffy, Luka Brcic, Viktória László, Balázs Döme, Judit Moldvay, Katalin Dezső, Martin Bilban, Helmut Popper, Herwig P. Moll & Emilio Casanova. (2019) JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression. International Journal of Cancer 145:12, pages 3376-3388.
Crossref
Crossref
Rebecka Hellsten, Lisa Lilljebjörn, Martin Johansson, Karin Leandersson & Anders Bjartell. (2019) The STAT3 inhibitor galiellalactone inhibits the generation of MDSC‐like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors. The Prostate 79:14, pages 1611-1621.
Crossref
Crossref
Siqi Chen, Derek A Wainwright, Jennifer D Wu, Yong Wan, Daniela E Matei, Yi Zhang & Bin Zhang. (2019) CD73: an emerging checkpoint for cancer immunotherapy. Immunotherapy 11:11, pages 983-997.
Crossref
Crossref
Nienke de Haas, Coco de Koning, Stefania di Blasio, Georgina Flórez-Grau, I. Jolanda M. de Vries & Stanleyson V. Hato. (2019) STAT Family Protein Expression and Phosphorylation State during moDC Development Is Altered by Platinum-Based Chemotherapeutics. Journal of Immunology Research 2019, pages 1-12.
Crossref
Crossref
Silvia Martin Lluesma, Michele Graciotti, Cheryl Chiang & Lana Kandalaft. (2018) Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?. Vaccines 6:4, pages 79.
Crossref
Crossref
Fatima Valdes-Mora, Kristina Handler, Andrew M. K. Law, Robert Salomon, Samantha R. Oakes, Christopher J. Ormandy & David Gallego-Ortega. (2018) Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology. Frontiers in Immunology 9.
Crossref
Crossref
Luca Cassetta & Jeffrey W. Pollard. (2018) Targeting macrophages: therapeutic approaches in cancer. Nature Reviews Drug Discovery 17:12, pages 887-904.
Crossref
Crossref
Olga S. Blomberg, Lorenzo Spagnuolo & Karin E. de Visser. (2018) Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. Disease Models & Mechanisms 11:10.
Crossref
Crossref
Antero Salminen, Kai Kaarniranta & Anu Kauppinen. (2018) Phytochemicals inhibit the immunosuppressive functions of myeloid-derived suppressor cells (MDSC): Impact on cancer and age-related chronic inflammatory disorders. International Immunopharmacology 61, pages 231-240.
Crossref
Crossref
Luca Cassetta & Takanori Kitamura. (2018) Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors. Frontiers in Cell and Developmental Biology 6.
Crossref
Crossref
Chiou-Feng Lin, Chih-Ming Lin, Kang-Yun Lee, Szu-Yuan Wu, Po-Hao Feng, Kuan-Yuan Chen, Hsiao-Chi Chuang, Chia-Ling Chen, Yu-Chih Wang, Po-Chun Tseng & Tsung-Ting Tsai. (2017) Escape from IFN-γ-dependent immunosurveillance in tumorigenesis. Journal of Biomedical Science 24:1.
Crossref
Crossref
Diana Shinko, Connie I. Diakos, Stephen J. Clarke & Kellie A. Charles. (2017) Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine. Clinical Pharmacology & Therapeutics 102:4, pages 599-610.
Crossref
Crossref
Sonja I. Buschow, Matteo Ramazzotti, Inge M.J. Reinieren-Beeren, Lucie M. Heinzerling, Harm Westdorp, Irene Stefanini, Luca Beltrame, Stanleyson V. Hato, Eva Ellebaek, Stefanie Gross, Van Anh Nguyen, Georg Weinlich, Jiannis Ragoussis, Dilair Baban, Beatrice Schuler-Thurner, Inge M. Svane, Nikolaus Romani, Jonathan M. Austyn, I. Jolanda M. De Vries, Gerold Schuler, Duccio Cavalieri & Carl G. Figdor. (2017) Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein. Oncotarget 8:40, pages 67439-67456.
Crossref
Crossref
Anna Mondino, Gerlanda Vella & Laura Icardi. (2017) Targeting the tumor and its associated stroma: One and one can make three in adoptive T cell therapy of solid tumors. Cytokine & Growth Factor Reviews 36, pages 57-65.
Crossref
Crossref
Mansi Saxena & Nina Bhardwaj. (2017) Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. Current Opinion in Immunology 47, pages 35-43.
Crossref
Crossref
Jihao Zhou, Yushi Yao, Qi Shen, Guoqiang Li, Lina Hu & Xinyou Zhang. (2017) Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells. Journal of Cancer Research and Clinical Oncology 143:8, pages 1371-1380.
Crossref
Crossref
Priscilla S. Redd, Mohammed L. Ibrahim, John D. Klement, Sarah K. Sharman, Amy V. Paschall, Dafeng Yang, Asha Nayak-Kapoor & Kebin Liu. (2017) SETD1B Activates iNOS Expression in Myeloid-Derived Suppressor Cells. Cancer Research 77:11, pages 2834-2843.
Crossref
Crossref
Matthew Weinstock, Jacalyn Rosenblatt & David Avigan. (2017) Dendritic Cell Therapies for Hematologic Malignancies. Molecular Therapy - Methods & Clinical Development 5, pages 66-75.
Crossref
Crossref
Bertrand Allard, Maria Serena Longhi, Simon C. Robson & John Stagg. (2017) The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunological Reviews 276:1, pages 121-144.
Crossref
Crossref
Colleen S. Netherby & Scott I. Abrams. (2017) Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease. Cancer Immunology, Immunotherapy.
Crossref
Crossref